#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Experience with the prostate health index in daily clinical practice


Authors: Vojtěch Fiala;  Roman Sobotka;  Zuzana Vaľová;  Michal Pešl;  Tomáš Hradec;  Tomáš Hanuš;  Otakar Čapoun
Authors‘ workplace: Urologická klinika VFN a 1. LF UK v Praze
Published in: Ces Urol 2017; 21(4): 284-288
Category: Original Articles

Overview

 

Aim:
The use of prostate health index (PHI) for prostate cancer (PCa) diagnosis in patients with elevated prostate-specific antigen (PSA) level.

Methods:
Between 05/2015 and 05/2016 we performed 230 PHI examinations. We recorded age, PSA and free to total PSA ratio (f/tPSA) before the indication of PHI, PSA, f/tPSA and [-2]proPSA level measured in PHI calculation, size of the prostate, digital rectal examination finding and histology result in case of a prostate biopsy (PB). The distribution of parameters in different groups and subgroups was assessed by nonparametric tests and their correlation by Spearman’s correlation coefficient.

Results:
Median of age was 66 years (60–71). Median PSA level before indication of PHI was 6.1 ng/ml (4.1–9.4). Median of phi was 34.9 (26.7–48.2). Median prostate size was 40 ml (28–60 ml). Information about follow up after PHI measurement was available in 217 (94.4 %) patients until 01/2017. Repeated examination of PSA or phi only was indicated in 134 (61.8 %) cases. Prostate biopsy was indicated in 71 (32.7 %) men and cancer was found in 23 (32.4 %) patients. Only the phi result was not related to the size of prostate (p=0.4708). From laboratory parameters were significant for prediction of PB only fPSA/PSA ratio measured before phi count (p=0.0217) and phi density (0.0209). The phi result was significantly higher in patients indicated to PB (mean 71.3 vs. 29.6; p=0.001)

Conclusion:
The use of PHI in daily clinical practice improves indication of rebiopsy. PHI to prostate size ratio is the best predictor of PCa diagnosis in rebiopsy.

Key words:
Clinical practice, prostate biopsy, prostate cancer, prostate health index, prostate specific antigen.


Sources

1. Mužík J, Dušek L, Babjuk M, et al. Uroweb – webový portál pro analýzu a vizualizaci epidemiologie, diagnostiky a léčby urologických malignit [online]. Masarykova univerzita, Brno, 2017. (Přístup 9. 8. 2017).

Dostupný z WWW: http://www.uroweb.cz. ISSN 1804–6371. Verze 1.6d.

2. Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 2009; 9: 14.

3. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate‑specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19): 1542–1547.

4. Mikolajczyk S, Millar L, Wang T, et al. A precursor form of prostate‑specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60: 756-759.

5. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro‑prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185(5): 1650–1655.

6. Čapoun O, Sobotka R, Soukup V, et al. Prostate health index (phi) in primary diagnosis of prostate cancer. Eur Urol Suppl 2014; 13(6) e1222.

7. Fuchsová R, Topolčan O, Vrzalová J, et al. Přínos stanovení [-2]proPSA v diferenciální diagnostice karcinomu prostaty. Ces Urol 2014; 18(1): 21–25.

8. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate‑specific antigen in a community‑based population of healthy men. Establishment of age‑specific reference ranges. JAMA 1993 Aug 18; 270(7): 860–864.

Labels
Paediatric urologist Nephrology Urology

Article was published in

Czech Urology

Issue 4

2017 Issue 4

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#